NIKKEI 225
38,703.51 +213.34 (+0.55%) HANG SENG
18,476.80 +51.84 (+0.28%) CRUDE OIL
75.59 +1.52 (+2.05%) GOLD FUTURES
2,393.60 +18.10 (+0.76%) DOW
38,868.19 +60.86 (+0.16%) Bitcoin GBP
55,407.84 -46.74 (-0.08%)
GSK Jan 2026 40.000 put
- Fool.co.uk
Down 10% in a day! The GSK share price looks like a once-in-a-decade bargain buy
Harvey Jones didn't waste a second before taking advantage of a sharp drop in the GSK share price on Monday. Then the doubts set in. The post Down 10% in a day! The GSK share price looks like a once-in-a-decade bargain buy appeared first on The Motley Fool UK.
- Evening Standard
FTSE 100 Live 3 June: New York trading glitch sparks volatility, GSK shares tumble
GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.
- Benzinga
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or refractory multiple myeloma. The data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin comb
